Zymeworks (ZYME) Projected to Post Earnings on Wednesday

Zymeworks (NASDAQ:ZYME) is expected to announce its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect Zymeworks to post earnings of ($0.35) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 2, 2026 at 8:30 AM ET.

Zymeworks Price Performance

Shares of ZYME opened at $23.63 on Wednesday. Zymeworks has a one year low of $9.03 and a one year high of $28.49. The company has a 50-day simple moving average of $24.14 and a two-hundred day simple moving average of $20.59. The firm has a market capitalization of $1.77 billion, a PE ratio of -28.13 and a beta of 1.25.

Analysts Set New Price Targets

A number of research analysts have recently commented on ZYME shares. Wells Fargo & Company upgraded Zymeworks from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $25.00 to $33.00 in a research note on Friday, December 12th. Truist Financial assumed coverage on Zymeworks in a research report on Wednesday, December 17th. They set a “buy” rating and a $40.00 price objective for the company. Zacks Research cut shares of Zymeworks from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 26th. Citigroup assumed coverage on shares of Zymeworks in a research note on Wednesday, December 3rd. They issued an “outperform” rating for the company. Finally, B. Riley Financial reissued a “buy” rating and set a $40.00 price target (up from $30.00) on shares of Zymeworks in a research report on Friday, November 21st. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $32.90.

Insiders Place Their Bets

In related news, CEO Kenneth Galbraith sold 30,424 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $22.67, for a total transaction of $689,712.08. Following the sale, the chief executive officer directly owned 226,842 shares of the company’s stock, valued at $5,142,508.14. This trade represents a 11.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Jeffrey T. L. Smith sold 9,310 shares of Zymeworks stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $22.67, for a total value of $211,057.70. Following the completion of the sale, the executive vice president owned 26,708 shares of the company’s stock, valued at $605,470.36. The trade was a 25.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 187,933 shares of company stock worth $4,673,716 in the last 90 days. 33.51% of the stock is currently owned by company insiders.

Institutional Trading of Zymeworks

Institutional investors have recently made changes to their positions in the stock. Invesco Ltd. grew its stake in shares of Zymeworks by 175.0% in the fourth quarter. Invesco Ltd. now owns 257,580 shares of the company’s stock worth $6,782,000 after acquiring an additional 163,923 shares during the period. XTX Topco Ltd purchased a new stake in Zymeworks in the fourth quarter worth approximately $2,461,000. VARCOV Co. bought a new stake in Zymeworks in the 4th quarter worth approximately $259,000. Virtus Investment Advisers LLC grew its position in Zymeworks by 20.2% in the 4th quarter. Virtus Investment Advisers LLC now owns 10,441 shares of the company’s stock worth $275,000 after purchasing an additional 1,755 shares during the period. Finally, SummitTX Capital L.P. purchased a new stake in Zymeworks during the 4th quarter valued at $5,905,000. Hedge funds and other institutional investors own 92.89% of the company’s stock.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.